Dificid (fidaxomicin) - Merck (MSD), Astellas
'Extended-pulsed fidaxomicin versus conventional dosing in patients at high risk of recurrence of Clostridioides difficile infection' - Author's reply. (PubMed, Clin Microbiol Infect) - Sep 4, 2026 - No abstract available 
Journal • Infectious Disease
http://www.ncbi.nlm.nih.gov/pubmed/42692355
 
; Elena Rubio-Martín; Javier Cobo; Rosa Escudero-Sanchez
 
Sep 4, 2026
 
Prev Next